3,477 Shares in IQVIA Holdings Inc. $IQV Bought by Tempo Wealth LLC

Tempo Wealth LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,477 shares of the medical research company’s stock, valued at approximately $784,000.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC raised its position in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA in the 2nd quarter worth approximately $514,000. First Trust Advisors LP boosted its holdings in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after acquiring an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in shares of IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on IQV. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Finally, HSBC set a $210.00 price objective on shares of IQVIA in a research report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $222.56.

IQVIA Price Performance

Shares of NYSE:IQV opened at $168.14 on Friday. The company’s fifty day moving average is $173.72 and its two-hundred day moving average is $191.84. The company has a market cap of $28.06 billion, a P/E ratio of 20.84, a price-to-earnings-growth ratio of 1.46 and a beta of 1.21. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.